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Abstract
Synovial tissue of rheumatoid arthritis (RA) patients is
characterised by an influx and retention of CD97-positive
inflammatory cells. The ligands of CD97, CD55, chondroitin
sulfate B, and α5β1 (very late antigen [VLA]-5) are expressed
abundantly in the synovial tissue predominantly on fibroblast-like
synoviocytes, endothelium, and extracellular matrix. Based upon
this expression pattern, we hypothesise CD97 expression to
result in accumulation of inflammatory cells in the synovial tissue
of RA patients. To determine the therapeutic effect of blocking
CD97 in an animal model of RA, collagen-induced arthritis was
induced in a total of 124 DBA/J1 mice. Treatment was started
on day 21 (early disease) or on day 35 (longstanding disease)
with the blocking hamster anti-mouse CD97 monoclonal
antibody (mAb) 1B2, control hamster immunoglobulin, or NaCl,
applied intraperitoneally three times a week. The paws were
evaluated for clinical signs of arthritis and, in addition, examined
by radiological and histological analysis. Mice receiving 0.5 mg
CD97 mAb starting from day 21 had significantly less arthritis
activity and hind paw swelling. Furthermore, joint damage and
inflammation were reduced and granulocyte infiltration was
decreased. When treatment was started on day 35, CD97 mAb
treatment had similar effects, albeit less pronounced. The
results support the notion that CD97 contributes to synovial
inflammation and joint destruction in arthritis.
Introduction
Synovial tissue of patients with rheumatoid arthritis (RA) is
characterised by a striking increase in cellularity [1]. The accu-
mulation of inflammatory cells is probably due to multiple proc-
esses, including enhanced migration, local retention, and
proliferation of these cells as well as reduced apoptosis [2].
CD97 is a member of the epidermal growth factor (EGF)-
seven-span transmembrane (TM7) family [3] of TM7 adhesion
receptors [4,5]. These predominantly leukocyte-restricted cell-
surface proteins possess a large extracellular region contain-
ing multiple N-terminal EGF-like domains [3]. CD97 is
expressed by a wide range of leukocytes, including activated
lymphocytes, granulocytes, monocytes, macrophages, and
dendritic cells. Due to alternative mRNA splicing, isoforms
with three, four, and five EGF domains are expressed [5].
CD97 interacts with cellular ligands. All isoforms, albeit with
different affinity, bind CD55, which is also known as DAF
(decay accelerating factor) [6,7]. The largest isoform, in addi-
tion, interacts with the glycosaminoglycan chondroitin sulfate
B (dermatan sulfate) [8,9]. More recently, a third ligand of
CD97 was identified by demonstrating that the integrin α5β1
(very late antigen [VLA]-5) and possibly also αvβ3 binds the
Arg-Gly-Asp (RGD) motif in the stalk region of human CD97
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[10]. Recent functional studies have implicated a role of CD97
in leukocyte trafficking and angiogenesis [4,10].
We have previously shown CD97 to be abundantly expressed
by inflammatory cells in the synovial tissue of patients with RA
[11]. Furthermore, using fluorescent CD97 protein-covered
probes, we showed that interaction between CD97 and its lig-
ands CD55 and chondroitin sulfate B can indeed occur in syn-
ovial tissue of patients with RA [12]. Interestingly, all known
ligands of CD97 are abundantly expressed in the rheumatoid
synovium: CD55 on fibroblast-like synoviocytes and chondroi-
tin sulfate B as a component of the extracellular matrix [12-14].
In rheumatoid synovial tissue, chondroitin sulfate B has been
shown to be the primary molecular species of chondroitin sul-
fates in inflammatory areas [14]. Furthermore, α5β1 is one of
the predominant β1 integrins expressed by rheumatoid syno-
vial pannus and is expressed by cells in the intimal lining layer
and endothelial cells, especially in venules and capillaries
associated with lymphocyte aggregates [15].
Based upon the ability of CD97 to bind various ligands
expressed in RA synovial tissue and its abundant expression
on inflammatory cells, we hypothesise that CD97 expression
by infiltrating cells may be involved in migration and retention
of inflammatory cells in the inflamed synovium with a detrimen-
tal effect on RA. To test our hypothesis, we used a well-estab-
lished mouse model for RA, murine collagen-induced arthritis
(CIA) [16], to evaluate the potential effects of CD97 blockade.
Materials and methods
Animals
Male DBA/J1 mice were purchased from Harlan (Horst, The
Netherlands) and housed under conventional conditions at the
animal facility of the Academic Medical Center (Amsterdam,
The Netherlands). Feeding was ad libitum. All experiments
were approved by the animal ethical committee of the Aca-
demic Medical Center.
Preparation of CD97 monoclonal antibody
The hybridoma 1B2 [17] was grown in large amounts, and
monoclonal antibody (mAb) was purified using protein A-
Sepharose CL-4B (Sigma-Aldrich, St. Louis, MO, USA). Con-
tamination with lipopolysaccharide was detected by the Euro-
pean Endotoxin Testing Service (Cambrex Bio Science
Verviers S.p.r.l., Verviers, Belgium, formerly BioWhittaker
Europe s.p.r.l.) and did not exceed 10 EU/ml (890 pg/ml). The
CD97 mAb was diluted to the required concentration (0.25 or
0.5 mg in 100 µl 0.9% NaCl). Hamster immunoglobulin (Ig)
(Rockland, Gilbertsville, PA, USA) and 0.9% NaCl (tebu-bio,
Heerhugowaard, The Netherlands) were used as controls.
Induction and assessment of CIA
Bovine collagen type II (Chondrex, Inc., Redmond, WA, USA)
was mixed with complete Freund's adjuvant (CFA) (Chondrex,
Inc.) and injected intradermally on day 0 at the base of the tail
of 8- to 11-week-old mice (100 µg collagen type II and 100 µg
CFA in a total volume of 100 µl emulsion). On day 20, mice
received an intraperitoneal booster injection with 100 µg of
collagen type II in phosphate-buffered saline (PBS).
The severity of the arthritis was assessed using a semi-quanti-
tative scoring system (0 to 4): 0, normal; 1, redness and/or
swelling in one joint; 2, redness and/or swelling in more than
one joint; 3, redness and/or swelling in the entire paw; and 4,
deformity and/or ankylosis [18,19]. Furthermore, hind paw
ankle joint thickness was measured using a dial caliper
(POCO 2T 0- to 10-mm test gauge; Kroeplin Längen-
messtechnik, Schlüchtern, Germany).
Treatment protocols and evaluation of arthritis activity
Our study was designed to examine whether, and at which
dosage, CD97 mAb treatment had an effect on CIA in different
phases of the disease. Three experiments were performed in
succession.
Experiment 1: To determine the optimal dosage, treatment
with NaCl, control Ig (cIg), or CD97 mAb (0.25 or 0.5 mg)
(eight mice per group) was started 24 hours after the collagen
booster. Mice were treated intraperitoneally three times a
week for a period of 28 days.
Experiments 2 and 3: To study the effect of treatment in early
arthritis compared with longstanding disease, treatment with
the optimal dosage was started 21 days (eight mice per
group) or 35 days (20 mice per group) after arthritis induction
in two successive experiments. We decided to include a larger
group of mice in experiment 3 because it is usually more diffi-
cult to achieve clinical improvement in longstanding disease.
Mice were treated three times a week for 28 or 14 days,
respectively.
Disease activity was monitored by clinical scoring of the paws
and measurements of the ankle diameter three times a week
by two researchers who had no knowledge of the treatment
groups [19]. Cages (four mice per cage) were matched for
arthritis score before random assignment to treatment. At the
end of the experiment, mice were sacrificed and paws were
collected for radiological and histological evaluation. Further-
more, inguinal lymph nodes and spleen were removed for in
vitro studies, and blood was collected.
Radiological analysis
The left hind paws were used for x-ray radiographic evaluation.
Joint destruction was scored on a scale from 0 to 5 as
described before [20]: 0, no damage; 1, minor bone destruc-
tion observed in one enlightened spot; 2, moderate changes,
two to four spots in one area; 3, marked changes, two to four
spots in multiple areas; 4, severe erosions afflicting the joint;
and 5, complete destruction of the joints. The radiographs
were scored by observers without knowledge of the treatmentAvailable online http://arthritis-research.com/content/8/5/R155
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groups. Minor differences between the observers were
resolved by mutual agreement.
Histological analysis
Arthritic paws were fixed in 10% buffered formalin for 48 hours
and decalcified in 15% EDTA (ethylenediaminetetraacetic
acid) in buffered 5.5% formalin. The paws were then embed-
ded in paraffin, and 5-µm saggital serial sections of whole hind
paws were cut. Tissue sections were stained with haematoxy-
lin and eosin or safranin O fast green.
Inflammation was graded on a scale from 0 (no inflammation)
to 3 (severely inflamed joint) based on infiltration by inflamma-
tory cells in the synovium. Bone erosions were scored using a
semi-quantitative scoring system from 0 (no erosions) to 3
(extended erosions and destruction of bone) [20]. Sections
were also stained with safranin O fast green to determine the
loss of proteoglycans. Safranin O staining was scored with a
semi-quantitative scoring system (0 to 3), in which a score of
0 represents no loss of proteoglycans and a score of 3 indi-
cates complete loss of staining for proteoglycans [21].
Furthermore, a tartrate-resistant acid phosphatase (TRAP)
staining was performed to detect the presence of osteoclasts
(Sigma-Aldrich). TRAP staining was scored semi-quantita-
tively (on a scale from 0 to 4): 0, no osteoclasts per paw; 1, 1
to 10 osteoclasts per paw; 2, 11 to 20 osteoclasts per paw;
3, 21 to 50 osteoclasts per paw; and 4, more than 50 osteo-
clasts per paw.
Immunohistochemistry
Immunohistochemical staining on sequential sections (8 to 12
paws per group) was performed to detect Ly-6-positive gran-
ulocytes (clone RB6-8C5; BD Pharmingen, San Diego, CA,
USA), F4/80-positive macrophages (clone 6F12; BD
Pharmingen), and CD3-positive T cells (clone A0452; Dako,
Carpinteria, CA, USA). For control sections, the primary mAb
was omitted or irrelevant IgG was applied. The sections were
washed with PBS between all steps, unless otherwise speci-
fied. Paraffin-embedded sections (5 µm) were dewaxed using
xylene and dehydrated in a gradient of alcohols. Endogenous
peroxidase activity was quenched with methanol and 0.3%
H2O2.
For Ly-6 staining, the slides were treated with 0.25% pepsine
in 0.1 M HCl at 37°C. After preincubation with PBS containing
10% normal goat serum, Ly-6G-fluorescein isothiocyanate
(FITC) was applied and incubated for 3 hours at room temper-
ature. Thereafter, the slides were incubated with rabbit anti-
FITC (Dako) for 30 minutes. Subsequently, the slides were
incubated with PowerVision goat anti-rabbit poly-horseradish
peroxidase (HRP) (ImmunoVision Technologies, Co., Bris-
bane, CA, USA).
For F4/80 staining, antigen retrieval was performed by heating
the sections for 5 minutes at 95°C in 0.1 M citric acid at pH
6.0. Slides were preincubated with PBS containing 10% nor-
mal goat serum. Then, F4/80 rat IgG2b was applied and incu-
bated overnight at 4°C, followed by biotinylated rabbit anti-rat
(BD Pharmingen) in PBS with 5% human pool serum for 30
minutes. Subsequently, avidin-biotin complex was applied
(ABC-kit; Dako).
For CD3 staining, slides were subsequently kept in EDTA/Tris
(pH 9.0) overnight at 60°C, preincubated with PBS containing
10% normal goat serum, incubated with rabbit anti-human
CD3 overnight at 4°C, and treated with PowerVision goat anti-
rabbit poly-HRP.
For all stainings, HRP activity was detected using H2O2 as
substrate and DAB (diaminobenzidin) as dye. All sections
were briefly counterstained with Mayer's haemalum solution.
All sections were analysed in a blinded manner by two inde-
pendent observers. After immunohistochemical staining,
expression of the different markers in the synovial tissue of
ankle and knee joints was scored semi-quantitatively on a four-
point scale [21]. A score of 0 represented minimal expression,
whereas a score of 3 represented abundant expression of a
marker. Minor differences between the observers were
resolved by mutual agreement.
In vitro assays on lymph node cells and splenocytes
Single-cell suspensions were obtained by crushing spleens or
lymph nodes through a 40-µm cell strainer (BD Pharmingen,
Franklin Lakes, NJ, USA). The erythrocytes of the spleen cell
suspension were lysed with ice-cold isotonic NH4Cl solution
(155 mM NH4Cl, 10 mM KHCO3, and 100 mM EDTA, pH
7.4), and the remaining cells were washed twice. Splenocytes
and lymph node cells were resuspended in Dulbecco's modi-
fied Eagle's medium (DMEM) (Cambrex Bio Science Walkers-
ville, Inc., Walkersville, MD, USA, formerly BioWhittaker, Inc.)
containing 10% fetal calf serum and 1% antibiotic-antimycotic
solution (Invitrogen, Carlsbad, CA, USA, formerly Life Technol-
ogies, Inc.), seeded in 96-well round-bottom culture plates at
a cell density of 1 × 106 cells (splenocytes) or 1 × 105 cells
(lymph node cells) (in triplicate), and stimulated with 10 µg/ml
collagen (Chondrex, Inc.). In a separate experiment, round-bot-
tom plates were coated overnight with anti-CD3 (clone
145.2c11; BD Pharmingen) and washed twice with sterile
PBS. Aliquots of 1 × 106 cells (splenocytes) or 1 × 105 cells
(lymph node cells) (in triplicate) were added to each well and
diluted with DMEM containing anti-CD28 (clone 37.51; BD
Pharmingen). Supernatants of both experiments were har-
vested after a 48-hour incubation period at 37°C in 5% CO2.
Enzyme-linked immunosorbent assay
Cytokine and anti-collagen antibody (Ab) levels were detected
by enzyme-linked immunosorbent assay (ELISA). InterleukinArthritis Research & Therapy    Vol 8 No 5    Kop et al.
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(IL)-6, IL-10, and interferon-γ (IFN-γ) (BD Pharmingen) assays
were performed according to the manufacturer's instructions.
Detection limits were 20 pg/ml for IL-6 and 30 pg/ml for IL-10
and IFN-γ. Anti-collagen Ig was detected using the anti-bovine
collagen Ab detection kit (Chondrex, Inc.).
Statistical analysis
To evaluate the effects of the different treatments, we deter-
mined the change in arthritis scores (delta arthritis score) and
caliper measurements (delta ankle joint swelling). Delta scores
were calculated by subtracting the scores of day 21 (experi-
ments 1 and 2) or the scores of day 35 (experiment 3) from the
measured scores of days 23 to 49 (experiments 1 and 2) or
37 to 49 (experiment 3), as described previously [22].
Delta clinical scores, delta caliper measurements, and radio-
logical and histologic scores were compared using non-para-
metric tests (Kruskal-Wallis followed by Mann-Whitney U).
Areas under the curve were calculated for the delta clinical
scores and delta caliper measurements of each mouse and
were compared using one-way analysis of variance (ANOVA),
followed by Student t test, because the Kolmogorov-Smirnov
test showed normal distribution. Incidence was compared
using Kaplan-Meier survival analysis. For the evaluation of the
incidence, mice were considered to have arthritis if they had
an increase compared with baseline of at least two points.
Mice suffering from arthritis before or at the onset of treatment
were excluded from the incidence calculation. Cytokine levels
and collagen-specific Ig levels were compared using one-way
ANOVA/Student t test.
Results
CD97 blockade reduces arthritis activity
We first investigated the effect of CD97 mAb treatment on
CIA when initiated 21 days after the induction of arthritis
(experiment 1). Mice received NaCl, cIg (0.5 mg), or the CD97
mAb 1B2 (0.25 or 0.5 mg) three times a week starting 24
hours after the booster. No statistical difference was found
between the control groups. Mice treated with CD97 mAb had
reduced signs of arthritis, in a dose-dependent fashion (Figure
1a). The beneficial effect was maximal when mice were treated
with the 0.5 mg dosage (P < 0.05 on days 30 up to 42). The
areas under the curve for the delta arthritis scores were signif-
icantly reduced in the CD97 mAb group (P < 0.05) (Figure
1b). Similar results were obtained using caliper measure-
ments, although the dose dependency was not as prominent
(P < 0.05 on days 30 and 35 up to 42) (Figure 2a). This lack
of dose response might be explained by the fact that, for cali-
per measurements, only the diameter of the ankles of the hind
paws is evaluated, whereas clinical arthritis scores also take
into account redness, and all joints of all four paws are
included. The areas under the curve for the delta caliper
scores were significantly reduced in the CD97 mAb group (P
< 0.05) (Figure 2b).
Next, we performed independent experiments 2 and 3 using
the same approach, starting treatment at different stages of
the disease. We confirmed the beneficial effect of CD97
blockade using the high (0.5 mg) dosage in early arthritis.
CD97 mAb-treated mice had significantly lower arthritis
scores (Figure 1c,d) and ankle joint swelling (Figure 2c,d). The
results in chronic arthritis (treatment started at day 35) were
similar, although not as pronounced compared with early initi-
ation of treatment (Figures 1e,f and 2e,f).
CD97 blockade reduces the synovial cell infiltrate
The effect of CD97 mAb on synovial inflammation was
assessed by histology and immunohistochemistry. Haematox-
ylin and eosin staining revealed a significant reduction in
inflammation in the group that received treatment from day 21
on (Figure 3a,b). This effect was also observed when treat-
ment was started at day 35, although the difference did not
reach statistical significance (Figure 3d).
We subsequently applied immunohistochemical analysis to
see whether different leukocyte subsets were evenly
decreased by CD97 mAb treatment. A consistent trend
toward reduced granulocyte numbers was found in the CD97
mAb-treated groups, irrespective of the start of treatment
(granulocytes mean immunohistological score ± standard
error of the mean [SEM] on day 21: NaCl 1.6 ± 0.4, cIg 1.6 ±
0.5, CD97 mAb 0.9 ± 0.4, P = 0.3; on day 35: NaCl 0.8 ± 0.4,
cIg 1.8 ± 0.4, CD97 mAb 0.4 ± 0.2, P = 0.09 [n = 8 to 12 per
group]). There were no significant differences in macrophage
and T-cell numbers (data not shown).
CD97 blockade protects against joint damage
Treatment with CD97 mAb at the onset of symptoms signifi-
cantly reduced bone erosions as detected by x-ray analysis
(Figure 4a–c). No difference was found when treatment was
started on day 35, presumably due to the fact that irreversible
bone damage had already occurred before the treatment was
initiated (Figure 4d).
Histological analysis confirmed a significant reduction in ero-
sions in the group that received CD97 mAb treatment from
day 21 on (Figure 3c). This effect was also observed, albeit to
a lesser extent, when treatment was started at day 35 (Figure
3e). Subsequently, cartilage destruction was assessed by
safranin O staining, a method to detect proteoglycan deple-
tion. A consistent, protective effect was observed in the group
treated from day 21 on, but the differences did not reach sta-
tistical significance (Figure 5a–c).
TRAP staining showed low numbers of osteoclasts in all
groups, irrespective of treatment, suggesting bone loss had
already occurred at the time of sacrifice (TRAP mean score ±
SEM on day 21: NaCl 0.5 ± 0.3, IgG 0.4 ± 0.2, CD97 mAb
0.3 ± 0.3, P = 0.7 [n = 4 to 8 per group]).Available online http://arthritis-research.com/content/8/5/R155
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CD97 blockade does not affect serum levels of cytokine 
and anti-collagen Abs
We finally assessed the possibility that CD97 mAb treatment
affects B- or T-cell function. Measurement of collagen-induced
IL-6 and Ab production revealed no significant difference
between CD97 mAb-treated mice and control mice (Table 1).
To explore whether treatment had an effect on the Th1/Th2
balance, draining lymph nodes and spleen were isolated on
day 50 and stimulated with collagen, CD3/CD28, or culture
medium. IL-10 and IFN-γ levels were measured by ELISA. No
significant difference was found in cytokine production (Table
2), suggesting that CD97 mAb did not exert its beneficial
effect on CIA primarily by influencing cytokine profiles in the
lymphoreticular system.
Discussion
In this study, we observed a significant decrease in arthritis
severity after blocking CD97, especially when treatment was
initiated in early disease. The effects were, in general, dose-
dependent. Of importance, CD97 mAb treatment also pro-
tected against joint destruction in early arthritis. The beneficial
effects could not be explained by an effect on cytokine profiles
in the lymphoreticular system or the humoral response. Con-
ceivably, CD97 blockade exerts its effects by interference with
the binding of CD97-positive leukocytes to the ligands CD55
and/or chondroitin sulfate B, leading to a reduction of the syn-
ovial cell infiltrate.
Consistent with this notion, recent studies have shown an
effect of anti-CD97 treatment on cell migration in mouse mod-
els of infection and inflammation. In Streptococcus pneumo-
niae-induced pneumonia, in which clearance of the bacteria is
strongly dependent on neutrophil function, CD97 blockade
Figure 1
CD97 monoclonal antibody (mAb) treatment ameliorates arthritis activity in a dose-dependent manner CD97 monoclonal antibody (mAb) treatment ameliorates arthritis activity in a dose-dependent manner. Mice were treated with NaCl (■ ), 0.5 mg con-
trol immunoglobulin (cIg) (•), or 0.25 mg (❍ ) or 0.5 mg () anti-CD97 mAb. Delta arthritis scores were calculated by subtracting the score at the day 
of initiation of treatment from the measured score. Values are mean ± standard error of the mean. Areas under the curve (AUCs) were calculated for 
the delta clinical scores of each mouse. Experiment 1 (a,b) was performed to find an effective dosage of the CD97 mAb. Mice were treated from day 
21 on (n = eight mice per group). In experiments 2 and 3, the effect of treatment in early (c,d) and longstanding (e,f) disease was studied. Treatment 
was started from day 21 (eight mice per group) or day 35 (20 mice per group) on, respectively. *P < 0.05.Arthritis Research & Therapy    Vol 8 No 5    Kop et al.
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prevented neutrophil migration to the lungs [17]. This resulted
in enhanced outgrowth of bacteria in the lungs and reduced
survival. In addition, neutrophils incubated with CD97 mAb
failed to home to the gut in a model of experimental colitis [17].
In the early phase of CIA, the synovial tissue is characterised
by massive infiltration of predominantly polymorphonuclear
cells followed by an influx of mononuclear cells. During this
acute phase, formation of erosive pannus tissue and remode-
ling of the joint occur. The active inflammatory process sub-
sides 3 to 4 weeks after the onset of disease, leaving a
destroyed joint [16,23,24]. Clinical signs of arthritis usually
occur between days 21 and 28, and the inflammation starts to
become quiescent after day 42. This could be one of the rea-
sons that the beneficial effect of CD97 blockade on arthritis
was more modest in longstanding arthritis compared with early
treatment, given that cell infiltration already tends to decrease
in later stages of the disease.
Still, we did observe a significant reduction in arthritis activity
even when treatment was initiated in chronic arthritis. The
natural course of CIA could also explain the relatively small dif-
ferences in cellularity shown for individual cell populations by
immunohistochemistry, given that the tissue samples were
obtained not earlier than day 49. In the synovium, we detected
significantly reduced overall cellularity, as shown by conven-
tional histology, and a trend toward reduced granulocyte infil-
tration. However, we cannot exclude the possibility that other
synovial cells were affected as well during earlier phases of the
treatment.
The results presented here show that early anti-CD97 treat-
ment may protect against joint damage. The process of degra-
dation of the integrity of the joint is, at least in part, dependent
on the inflammatory process [25]. Osteoclasts play a crucial
role in the development of bone erosions and these cells are
derived from monocytes infiltrating the synovial tissue [26].
Figure 2
CD97 monoclonal antibody (mAb) treatment reduces ankle joint swelling CD97 monoclonal antibody (mAb) treatment reduces ankle joint swelling. Mice were treated with NaCl (■ ), 0.5 mg control immunoglobulin (cIg) (•), 
or 0.25 mg (❍ ) or 0.5 mg () anti-CD97 mAb. Delta hind paw ankle joint swelling was calculated by subtracting the diameter on the day of initiation 
of treatment from the measured diameter. Values are mean ± standard error of the mean. Areas under the curve (AUCs) were calculated for the delta 
caliper measurements of each mouse. Experiment 1 (a,b) was performed to find an effective dosage of the CD97 mAb. Mice were treated from day 
21 on (n = eight mice per group). In experiments 2 and 3, the effect of treatment in early (c,d) and longstanding (e,f) disease was studied. Treatment 
was started from day 21 (eight mice per group) or day 35 (20 mice per group) on, respectively. *P < 0.05.Available online http://arthritis-research.com/content/8/5/R155
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Together with fibroblast-like synoviocytes, synovial tissue
macrophages are also involved in the production of mediators
of degradation that are involved in the degradation of cartilage
matrix [1]. Thus, strategies interfering with migration and reten-
tion of inflammatory cells may protect bone and cartilage
against destruction. Consistent with this notion, the present
study showed a protective effect of CD97 blockade in early
disease. Because destruction of cartilage and bone occurs in
the early phase of CIA, the observation that initiation of
treatment in chronic disease did not result in reduced destruc-
tion is probably due to the fact that irreversible bone damage
had already occurred before the treatment was initiated.
As described above, human CD97 exists in three isoforms and
has several ligands, including CD55 [6], chondroitin sulfate B
[8], and α5β1 [10]. There are also three isoforms of murine
CD97 [27,28]. In addition to isoforms with three and four EGF
domains, a third isoform exists with an intervening sequence of
45 amino acids between the second and third EGF domains
which does not show homology to known protein modules.
Figure 3
CD97 monoclonal antibody (mAb) treatment protects against inflammation and erosion when treatment is started at the onset of symptoms CD97 monoclonal antibody (mAb) treatment protects against inflammation and erosion when treatment is started at the onset of symptoms. Mice 
were treated with NaCl, 0.5 mg control immunoglobulin (cIg), or 0.5 mg anti-CD97 mAb. Paws (n = 8 to 12 mice per group) were stained with hae-
matoxylin and eosin. (a) Representative examples of joints showing intact (left) and destructed (right) cartilage derived from mice treated from day 
21 on with 0.5 mg CD97 mAb or cIg, respectively. Infiltration (b,c) and erosion (d,e) scores of mice treated from day 21 (b,d) or day 35 (c,e) on. Val-
ues are mean ± standard error of the mean. *P < 0.05.Arthritis Research & Therapy    Vol 8 No 5    Kop et al.
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Murine CD97 has an expression profile similar to human
CD97 [27,28], and its EGF domains presumably recognise
the same ligands. Although EGF domains 1 and 2 mediate
binding to CD55 [17], interaction of EGF domain 3 (the
homolog of EGF domain 4 in humans [28]) still needs to be
formally shown. In contrast to human CD97, murine CD97
lacks an RGD motif in the stalk region [27,28] which facilitates
integrin binding in humans [10].
The 1B2 mAb used in this study blocks binding to CD55 [17].
This molecule is expressed by endothelial cells and fibroblast-
like synoviocytes, and blocking the interaction between CD97-
positive leukocytes and CD55-expressing cells in the syn-
ovium might explain, in part, the beneficial effects of CD97
blockade in the CIA model. In contrast, it has been reported
that mice deficient of CD55 have accelerated autoimmune dis-
ease [29-31], an effect that is thought to be attributable mainly
to the missing complement-regulating function of CD55 in
these mice. So far, CD97 has never been shown to affect the
complement-regulatory capacity of CD55. One might hypoth-
esise that CD55 through its interaction with CD97 provides an
additional, complement-independent molecular function.
We cannot completely exclude the possibility that the mAb
used in this study abrogated binding to chondroitin sulfate B
in addition to blocking binding to CD55. Although 1B2 does
not block chondroitin sulfate B binding in vitro [17], it could
sterically hinder this interaction in vivo. This notion is
supported by the observation that the effects of treatment with
the 1B2 mAb were similar to those using the 1C5 mAb that
interferes with EGF domain 3 (expected to block binding to
chondroitin sulfate B) in the S. pneumoniae-induced
pneumonia model [17]. The exact molecular mechanism by
which the mAb 1B2 inhibits infiltration of CD97-positive cells
in the synovium needs to be elucidated in future studies.
Figure 4
CD97 monoclonal antibody (mAb) treatment reduces bone damage when initiated at the onset of arthritis CD97 monoclonal antibody (mAb) treatment reduces bone damage when initiated at the onset of arthritis. Mice were treated with NaCl, 0.5 mg con-
trol immunoglobulin (cIg), or 0.25 mg or 0.5 mg anti-CD97 mAb. X-rays of hind paws (n = 8 to 20 mice per group) were analysed for erosions. (a) 
Representative x-rays of paws showing no bone or joint abnormalities (left) and complete bone destruction (right) derived from mice treated from day 
21 on with 0.5 mg CD97 mAb or cIg, respectively. (b-d) Radiological scores of mice treated from day 21 (b,c) or day 35 (d) on, corresponding with 
the experiments 1, 2, and 3, respectively (Figures 1 and 2). Values are mean ± standard error of the mean. *P < 0.05.Available online http://arthritis-research.com/content/8/5/R155
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The increased expression of CD97 in rheumatoid synovial tis-
sue [11], the interaction between CD97 and its ligands which
may occur in the synovium [12], and the beneficial effects of
anti-CD97 treatment in an animal model of RA, as presented
in this study, suggest a therapeutic potential of CD97 block-
ade. It has previously been proposed that blocking proinflam-
matory cell migration might be sufficient to achieve clinical
improvement in RA [32,33]. In addition to inhibiting cell migra-
tion, CD97 blockade could interfere with neoangiogenesis,
which is intimately involved in the pathogenesis of RA [2].
Recent work has shown that the integrin-binding RGD motif of
human CD97 is able to induce angiogenesis [10]. Obviously,
the clinical potential of anti-CD97 treatment needs to be inves-
tigated in clinical trials. The present study supports the ration-
ale for such trials.
Figure 5
CD97 monoclonal antibody (mAb) treatment protects against proteoglycan depletion CD97 monoclonal antibody (mAb) treatment protects against proteoglycan depletion. Mice were treated with NaCl, 0.5 mg control immunoglobulin 
(cIg), or 0.5 mg anti-CD97 mAb. Paws were stained with safranin O (n = 8 to 12 per group). (a) Representative examples of joints with normal (left) 
and depleted (right) proteoglycan derived from mice treated from day 21 on with 0.5 mg CD97 mAb or cIg, respectively. (b,c) Staining scores of 
mice treated from day 21 (b) or day 35 (c) on. Values are mean ± standard error of the mean.
Table 1
Serum levels of IL-6 and anti-collagen Ab do not differ between 
CD97 mAb-treated and control groups (mean ± SEM)
NaCl cIga CD97 mAba
IL-6 (pg/ml)
Treatment started on day 21 28 ± 4 28 ± 4 20 ± 1
Treatment started on day 35 24 ± 3 29 ± 5 23 ± 3
Anti-collagen Ab (µg/ml)
Treatment started on day 21 2,186 ± 592 1,539 ± 499 1,001 ± 199
Treatment started on day 35 494 ± 143 600 ± 137 578 ± 135
aMice were treated with 0.5 mg. Ab, antibody; cIg, control 
immunoglobulin; IL-6, interleukin-6; mAb, monoclonal antibody; SEM, 
standard error of the mean.
Table 2
Cytokine secretion by stimulated splenocytes or lymph node 
cells does not differ between CD97 mAb-treated and control 
groups (mean ± SEM)
NaCl cIga CD97 mAba
Interleukin-10 (pg/ml)
Splenocytes 49 ± 11 53 ± 14 76 ± 29
Lymph node cells 35 ± 5 31 ± 3 78 ± 27
Interferon-γ (pg/ml)
Splenocytes 76 ± 11 65 ± 15 156 ± 33
Lymph node cells 98 ± 28 76 ± 12 204 ± 62
aMice were treated with 0.5 mg. cIg, control immunoglobulin; mAb, 
monoclonal antibody; SEM, standard error of the mean.Arthritis Research & Therapy    Vol 8 No 5    Kop et al.
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Taken together, the results presented here support the view
that the interaction between CD97 and its ligands is involved
in cell migration to the site of inflammation in arthritis. We have
shown for the first time the potential of CD97 blockade as a
novel therapeutic strategy to reduce synovial inflammation and
joint destruction in a model of RA.
Conclusion
We postulate CD97 to be involved in migration and retention
of inflammatory cells in the inflamed synovium with a
detrimental effect on RA. To test this hypothesis, we investi-
gated the effect of a CD97-blocking mAb in CIA. Treatment of
mice starting from day 21 on (early disease) significantly
reduced arthritis activity and joint damage. Treatment started
on day 35 (longstanding disease) had similar, albeit less-pro-
nounced, effects. These results imply that blockade of CD97
might be potentially useful in the treatment of RA.
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